drugset / Trial / NCT01586364
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
NaSingle-groupOpen-labelTreatment
Summary
The objective of the study was to assess the long-term safety of daily doses of ospemifene 60 mg in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women without a uterus.
Timeline
- Start
- 2006-05-08
- Primary completion
- 2008-11-21
- Completion
- 2008-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ospemifene | Other / unclassified | 60 mg | Oral |